Coherus BioSciences (CHRS) Narrows Q4 Loss
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.37 --0%
EPS Growth %: +39.4%
Financial Fact:
Gain from sale of office premises: 0
Today's EPS Names:
MLKN, KBH, WOR, More
EPS Growth %: +39.4%
Financial Fact:
Gain from sale of office premises: 0
Today's EPS Names:
MLKN, KBH, WOR, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q4 EPS of ($1.47), versus ($3.68) reported last year. Revenue for the quarter came in at $6.5 million, versus $1.2 million reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Here Group posts FY2026 results with $88M revenue, goodwill write-down
- Jefferies Starts Oversea-Chinese Banking Corp Ltd (OCBC:SP) (OVCHF) at Hold
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
